Bioblast Pharma Ltd. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
-
5.00
17.00
25.00
12.00
Gross Income
-
5.00
17.00
25.00
12.00
SG&A Expense
1,148.00
7,075.00
14,630.00
13,921.00
5,838.00
EBIT
1,148.00
7,080.00
15,476.00
13,946.00
5,850.00
Unusual Expense
-
-
-
1,907.00
105.00
Non Operating Income/Expense
3.00
21.00
39.00
43.00
1.00
Interest Expense
-
6.00
12.00
-
-
Pretax Income
1,145.00
7,022.00
15,341.00
15,806.00
5,917.00
Income Tax
-
-
24.00
216.00
28.00
Consolidated Net Income
1,145.00
7,022.00
15,365.00
16,022.00
5,945.00
Net Income
1,145.00
7,022.00
15,365.00
16,022.00
5,945.00
Net Income After Extraordinaries
1,145.00
7,022.00
15,365.00
16,022.00
5,945.00
Net Income Available to Common
1,145.00
7,022.00
15,365.00
16,022.00
5,945.00
EPS (Basic)
0.70
2.85
5.40
5.05
1.79
Basic Shares Outstanding
2,846.10
2,451.90
2,846.10
3,181.20
3,313.60
EPS (Diluted)
0.40
2.86
5.40
5.04
1.79
Diluted Shares Outstanding
2,846.10
2,451.90
2,846.10
3,181.20
3,313.60
EBITDA
-
7,075.00
15,459.00
13,921.00
5,838.00
Other Operating Expense
-
-
829.00
-
-
Non-Operating Interest Income
-
85.00
186.00
90.00
39.00
About Bioblast Pharma
View Profile
